Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

7/11/24 9:01:05 AM ET

$MYGN

$PSNL

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Medical Specialities

Health Care

Get the next $MYGN alert in real time by email

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Get the next $MYGN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MYGN
$PSNL

Company	Date	Price Target	Rating	Analyst
Myriad Genetics Inc. $MYGN	9/19/2024	$32.00	Equal-Weight	Morgan Stanley
Myriad Genetics Inc. $MYGN	8/28/2024	$35.00	Overweight	Wells Fargo
Myriad Genetics Inc. $MYGN	6/27/2024	$29.00	Sector Outperform	Scotiabank
Myriad Genetics Inc. $MYGN	6/3/2024	$20.00	Underperform	Jefferies
Myriad Genetics Inc. $MYGN	5/8/2024	$25.00 → $35.00	Market Perform → Outperform	Leerink Partners
Myriad Genetics Inc. $MYGN	12/21/2023	$23.00	Neutral	Piper Sandler
Myriad Genetics Inc. $MYGN	12/19/2023	$20.00	Equal Weight	Wells Fargo
Myriad Genetics Inc. $MYGN	12/14/2023	$23.00	Buy	Guggenheim

More analyst ratings

$MYGN
$PSNL
Financials

Live finance-specific insights

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a
10/30/24 8:00:00 AM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Personalis to Announce Third Quarter 2024 Financial Results
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the co
10/23/24 4:01:00 PM ET
$PSNL
Medical Specialities
Health Care
Personalis Reports Second Quarter 2024 Financial Results
Strong Revenue Growth of 35% Year-over-Year Driven by 117% Growth from Biopharma Business Raises 2024 Full Year Revenue Guidance Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2024, and provided recent business accomplishments. Recent Business Accomplishments Highlighted clinical performance of NeXT Personal® at the American Society of Clinical Oncology (ASCO) meeting in May Compelling breast cancer detection results were presented by Dr. Isaac Garcia-Murillas (Institute of Cancer Research, London) and Prof. Nicolas Turner (Royal Marsden NHS Foundation Trust UK). In this
8/7/24 4:01:00 PM ET
$PSNL
Medical Specialities
Health Care

$MYGN
$PSNL
Leadership Updates

Live Leadership Updates

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal Officer, Fox's responsibilities will encompass a wide range of areas, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquis
7/31/24 8:50:00 AM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's Health
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women's health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she will support internal and external efforts to increase access to, and equity around, genetic testing throughout a woman's health journey including family planning, pregnancy management and hereditary cancer risk assessment. "We're thrilled to welcome Dallas
2/15/24 4:05:00 PM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and clinical strategy to advance Myriad's oncology portfolio, which currently offers germline testing, tumor profiling and companion diagnostic options, including homologous recombinat
1/30/24 5:00:00 PM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

$MYGN
$PSNL
Press Releases

Fastest customizable press release news feed in the world

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a
10/30/24 8:00:00 AM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Personalis to Announce Third Quarter 2024 Financial Results
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the co
10/23/24 4:01:00 PM ET
$PSNL
Medical Specialities
Health Care
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventative genetic testing with a focus on high-risk populations. The collaboration combines the strengths of Myriad's high-quality hereditary cancer and reproductive genetics products, MyRisk® with RiskScore® and Foresight® Carrier Screen, with jscreen's trusted education and genetic care navigation program. Through the partnership, the jscreen program intends to reach hundreds of thousands of high-risk adults across the United States
10/16/24 9:00:00 AM ET
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Chat with this insight

Recent Analyst Ratings for $MYGN$PSNL

$MYGN$PSNL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Personalis Inc.

SEC Form SC 13G filed by Personalis Inc.

Amendment: SEC Form SC 13D/A filed by Personalis Inc.

$MYGN$PSNL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Diaz Paul J sold $343,950 worth of shares (15,000 units at $22.93), decreasing direct ownership by 2% to 962,378 units (SEC Form 4)

Chief Commercial Officer Verratti Mark covered exercise/tax liability with 8,363 shares, decreasing direct ownership by 3% to 289,277 units (SEC Form 4)

Chief Scientific Officer Muzzey Dale covered exercise/tax liability with 452 shares, decreasing direct ownership by 0.42% to 107,561 units (SEC Form 4)

$MYGN$PSNL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$MYGN$PSNL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Morgan Stanley initiated coverage on Myriad Genetics with a new price target

Wells Fargo initiated coverage on Myriad Genetics with a new price target

Scotiabank initiated coverage on Myriad Genetics with a new price target

Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

$MYGN$PSNL SEC Filings

Myriad Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Personalis Inc. filed SEC Form 8-K: Other Events

SEC Form EFFECT filed by Personalis Inc.

$MYGN$PSNL Financials

Live finance-specific insights

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Personalis to Announce Third Quarter 2024 Financial Results

Personalis Reports Second Quarter 2024 Financial Results

$MYGN$PSNL Market Insights

Live Market Insights

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Myriad Genetics Secures Second Patent To Enhance Tumor-Informed High-Definition Molecular Residual Disease (MRD) Assay

Personalis 13D Filing Shows Tempus AI Reported A 15.1% Stake In The Co As Of July 3, 2024

$MYGN$PSNL Leadership Updates

Live Leadership Updates

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's Health

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

$MYGN$PSNL Press Releases

Fastest customizable press release news feed in the world

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Personalis to Announce Third Quarter 2024 Financial Results

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

Recent Analyst Ratings for
$MYGN
$PSNL

$MYGN
$PSNL
Large Ownership Changes

$MYGN
$PSNL
Insider Trading

$MYGN
$PSNL
Analyst Ratings

$MYGN
$PSNL
Insider Purchases

$MYGN
$PSNL
SEC Filings

$MYGN
$PSNL
Financials

$MYGN
$PSNL
Market Insights

$MYGN
$PSNL
Leadership Updates

$MYGN
$PSNL
Press Releases